Zevra Therapeutics, Inc. (ZVRA) Misses Q3 EPS by 10c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q3 EPS of ($0.40), $0.10 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $2.89 million versus the consensus estimate of $3.38 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c